Home / United States / Eurofins Lancaster Laboratories, LLC
Drug factory · FDA FEI 2513291
Eurofins Lancaster Laboratories, LLC
2425 New Holland Pike, Lancaster, PA, United States
United States: 1
Problems found, fixed voluntarily at FDA's last inspection, Aug 26, 2025.
Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.
8 drug inspections on record since 2009: 6 with no problems, 2 with problems fixed voluntarily, 0 with FDA action.
What it does, for whom
Drug Role For NDC
Aflibercept Tests it
Regeneron Pharmaceuticals, Inc.
61755-005
Alirocumab Tests it
Regeneron Pharmaceuticals, Inc.
61755-020 , 61755-021
Azithromycin Tests it
Pfizer Laboratories Div Pfizer Inc
0069-3051 , 0069-3080
Buprenorphine Tests it
Indivior Inc.
12496-0100 , 12496-0300
Ciltacabtagene Autoleucel Tests it
Janssen Biotech, Inc.
57894-111
Clonidine Tests it
Mayne Pharma Inc.
51862-453 , 51862-454 , 51862-455
Cx-055611 Tests it
Moderna US, Inc.
80777-114 , 80777-115
Cytarabine and Daunorubicin Tests it
Jazz Pharmaceuticals, Inc.
68727-745
Daratumumab and Hyaluronidase (human Recombinant) Tests it
Janssen Biotech, Inc.
57894-503
Efanesoctocog Alfa Tests it
Bioverativ Therapeutics Inc.
71104-978 , 71104-979 , 71104-981 +3
Efbemalenograstim Alfa Tests it
Acrotech Biopharma Inc
72893-016
Esmolol Tests it
Hikma Pharmaceuticals USA Inc.
0641-2965
Hydrochlorothiazide and Irbesartan Tests it
Sanofi-Aventis U.S. LLC
0024-5855 , 0024-5856
Irbesartan Tests it
Sanofi-Aventis U.S. LLC
0024-5851 , 0024-5852
Ixazomib Tests it
Takeda Pharmaceuticals America, Inc.
63020-230 , 63020-390 , 63020-400
Levoketoconazole Tests it
Xeris Pharmaceuticals, Inc.
72065-003
Lonafarnib Tests it
Eiger BioPharmaceuticals, Inc.
73079-050 , 73079-075
Lunsotogene Parvec Tests it
Regeneron Pharmaceuticals, Inc.
61755-062
Mebrofenin Tests it
Bracco Diagnostics Inc.
0270-0083
Oxcarbazepine Tests it
Ajanta Pharma USA Inc.
27241-304 , 27241-305 , 27241-306
Pegcetacoplan Tests it
Apellis Pharmaceuticals, Inc.
73606-010 , 73606-020
Peramivir Tests it
BioCryst Pharmaceuticals, Inc. , Seqirus USA Inc.
72769-181 , 61364-181
Plazomicin Tests it
Cipla Therapeutics Inc. , Cipla USA., Inc.
80735-820 , 69097-820
Risperidone Tests it
Indivior Inc.
12496-0090 , 12496-0120
Tolvaptan Tests it
Otsuka America Pharmaceutical, Inc.
59148-079 , 59148-080 , 59148-082 +4
FDA inspection history
Ended Result Program Problems noted
Aug 26, 2025 Problems found, fixed voluntarily Drug Quality Assurance 2 Oct 17, 2019 No problems found Drug Quality Assurance — Sep 28, 2017 No problems found Drug Quality Assurance — Jun 19, 2015 No problems found Drug Quality Assurance — Jun 27, 2013 No problems found Drug Quality Assurance — May 17, 2012 No problems found Drug Quality Assurance — Sep 7, 2010 Problems found, fixed voluntarily Drug Quality Assurance 1 Oct 6, 2009 No problems found Drug Quality Assurance —
What inspectors wrote down
From FDA's Form 483 citations: conditions an investigator observed that may violate drug manufacturing rules, as FDA published them.
Aug 26, 2025 inspection
Microbiological testing 21 CFR 211.165(b) Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.Written record of investigation incomplete 21 CFR 211.192 Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
Sep 7, 2010 inspection
Calibration - at intervals, written program, remedial action 21 CFR 211.160(b)(4) The calibration of instruments is not done at suitable intervals with provisions for remedial action in the event accuracy and/or precision limits are not met.
Registered with FDA for: analysis.